爲防範中國藥企跟風，美國生物技術公司加強保密

核心觀點

U.S. biotech firms are tightening confidentiality measures to prevent Chinese competitors from replicating their drug development pipelines.
Breakthru Medicine and other companies avoid investor pitching and academic conferences to limit exposure of proprietary research.
Chinese biotech firms have demonstrated faster development cycles and lower costs, with some achieving results in half the time and at half the expense.
A 2025 report by Norstella shows a 5x increase in early-stage trials in China compared to a decade ago, while U.S. trials have stagnated.
Some large U.S. pharmaceutical companies are now acquiring early-stage Chinese drug candidates, such as Novo Nordisk’s acquisition of a China-based version of semaglutide.
In the oncology field, a Chinese company began competitive trials within six weeks of Amgen’s announcement, with over 10 independent projects entering clinical development within 18 months.
A former Beam Therapeutics employee joined Shanghai-based YolTech Therapeutics to develop a competing gene therapy for the same rare genetic disease, raising concerns about intellectual property leakage.

U.S. biotech firms are shifting from open innovation to closed, high-security models to protect R&D advantages.
China’s biotech sector is rapidly closing the innovation gap, with faster development and lower costs posing significant competitive threats.
There is growing concern over the ‘fast-follow’ phenomenon, where Chinese companies replicate Western drug mechanisms with minimal time and cost investment.
Regulatory efforts, such as proposed U.S. legislation to block investments in Chinese pharma and restrict data acceptance, reflect a strategic response to these competitive pressures.